^
    Back
    Association details:
    Biomarker:HER-2 positive
    Cancer:HER2 Positive Breast Cancer
    Drug:trastuzumab mafodotin (IKS014) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    IKS014 in Advanced Solid Tumors That Express HER2

    Excerpt:
    ...- HER2 positive solid tumors with expression defined as IHC3+, IHC2+/ISH+, or low HER2 expression defined as IHC2+ (ISH-) or IHC1+ (ISH- /+ or untested)....
    Trial ID:
    NCT05872295
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

    Excerpt:
    ...Histologically or cytologically confirmed HER2-positive unresectable locally advanced or metastatic breast cancer; 3....
    Trial ID:
    NCT05755048
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    FS-1502 in HER2-positive advanced breast cancer: Results from an open-label, phase 1 study.

    Published date:
    05/25/2023
    Excerpt:
    FS-1502 demonstrated very promising antitumor activity and was well tolerated in heavily pretreated HER2-positive BC, with mild eye toxicity and no related interstitial lung disease reported.
    DOI:
    10.1200/JCO.2023.41.16_suppl.3044
    Trial ID:
    FS-CY1502-Ph1-01